Phenotypes Associated with This Genotype

Genotype
MGI:5543401

• Allelic Composition: Tgfbr2^tm1.2Hlm/Tgfbr2^tm1.2Hlm; Tg(Col1a2-cre/ERT,-ALPP)7Cpd/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * DBA/2

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased prostate gland adenocarcinoma incidence ( J:204736 )

♂ • focal areas of prostate adenocarcinomas are seen by 17 weeks of age in tamoxifen treated mice and these areas of adenocarcinoma expand throughout the life of mutants

♂ • prostates exhibit no regression acutely after castration, indicating castrate-resistant prostate cancer

♂ • administration of Sabutoclax (Bl-97C1), a pan-active Bcl2 protein family antagonist, mediates apoptosis in castrate-resistant prostate cancer cells of 36-week old mutant mice and reduces tumor size, however it has little apoptotic effect on benign prostate tissue

increased prostate intraepithelial neoplasia incidence ( J:204736 )

♂ • tamoxifen treated mice develop prostatic intraepithelial neoplasia (PIN) lesions in the prostate by 17 weeks of age, throughout each of the anterior and dorsolateral lobes with 100% penetrance

reproductive system

increased prostate gland adenocarcinoma incidence ( J:204736 )

♂ • focal areas of prostate adenocarcinomas are seen by 17 weeks of age in tamoxifen treated mice and these areas of adenocarcinoma expand throughout the life of mutants

♂ • prostates exhibit no regression acutely after castration, indicating castrate-resistant prostate cancer

♂ • administration of Sabutoclax (Bl-97C1), a pan-active Bcl2 protein family antagonist, mediates apoptosis in castrate-resistant prostate cancer cells of 36-week old mutant mice and reduces tumor size, however it has little apoptotic effect on benign prostate tissue

increased prostate intraepithelial neoplasia incidence ( J:204736 )

♂ • tamoxifen treated mice develop prostatic intraepithelial neoplasia (PIN) lesions in the prostate by 17 weeks of age, throughout each of the anterior and dorsolateral lobes with 100% penetrance

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:204736 )

♂ • focal areas of prostate adenocarcinomas are seen by 17 weeks of age in tamoxifen treated mice and these areas of adenocarcinoma expand throughout the life of mutants

♂ • prostates exhibit no regression acutely after castration, indicating castrate-resistant prostate cancer

♂ • administration of Sabutoclax (Bl-97C1), a pan-active Bcl2 protein family antagonist, mediates apoptosis in castrate-resistant prostate cancer cells of 36-week old mutant mice and reduces tumor size, however it has little apoptotic effect on benign prostate tissue

increased prostate intraepithelial neoplasia incidence ( J:204736 )

♂ • tamoxifen treated mice develop prostatic intraepithelial neoplasia (PIN) lesions in the prostate by 17 weeks of age, throughout each of the anterior and dorsolateral lobes with 100% penetrance

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:204736